Jacobson Kurt M, Hall Long Kirsten, McMurtry Erin K, Naessens James M, Rihal Charanjit S
Division of Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Qual Saf Health Care. 2007 Apr;16(2):154-9. doi: 10.1136/qshc.2006.019331.
Technological advances have enabled percutaneous coronary intervention (PCI) to be applied with expanding indications. However, escalating costs are of concern. This study assessed the incremental medical costs of major in-hospital procedural complications incurred by patients undergoing PCI.
We considered all patients undergoing elective, urgent, or emergent PCI at Mayo Clinic Rochester between 3/1/1998-3/31/2003 in analyses. Clinical, angiographic, and outcome data were derived from the Mayo Clinic PCI Registry. In-hospital PCI complications included major adverse cardiac and cerebrovascular events (MACCE) and bleeding of clinical significance. Administrative data were used to estimate total costs in standardised, year 2004, constant-US dollars. We used generalised linear modeling to estimate costs associated with complications adjusting for baseline and procedural characteristics.
1071 (13.2%) of patients experienced complications during hospitalisation. Patients experiencing complications were older, more likely to present with emergent PCI, recent or prior myocardial infarction, multi-vessel disease, and comorbid conditions than patients who did not experience these events. Unadjusted total costs were, on average, $27,865+/-$39,424 for complicated patient episodes compared to $12,279+/-$6796 for episodes that were complication free (p<0.0001). Adjusted mean costs were $6984 higher for complicated PCIs compared with uncomplicated PCI episodes (95% CI of cost difference: $5801, $8168). Incremental costs associated with isolated bleeding events, MACCE, or for both bleeding and MACCE events were $5883, $5086, and $15,437, respectively (p<0.0001).
This high-volume study highlights the significant economic burden associated with procedural complications. Resources and systems approaches to minimising clinical and economic complications in PCI are warranted.
技术进步使得经皮冠状动脉介入治疗(PCI)的应用指征不断扩大。然而,成本不断上升令人担忧。本研究评估了接受PCI治疗的患者发生主要院内手术并发症的增量医疗成本。
在分析中,我们纳入了1998年3月1日至2003年3月31日期间在罗切斯特梅奥诊所接受择期、紧急或急诊PCI的所有患者。临床、血管造影和结局数据来自梅奥诊所PCI注册中心。院内PCI并发症包括主要不良心脏和脑血管事件(MACCE)以及具有临床意义的出血。行政数据用于以2004年标准化不变美元估算总成本。我们使用广义线性模型来估算与并发症相关的成本,并对基线和手术特征进行调整。
1071名(13.2%)患者在住院期间发生并发症。与未发生这些事件的患者相比,发生并发症的患者年龄更大,更有可能接受急诊PCI、近期或既往心肌梗死、多支血管病变以及合并症。未调整的复杂患者事件的平均总成本为27,865美元±39,424美元,而无并发症事件的平均总成本为12,279美元±6,796美元(p<0.0001)。与未发生并发症的PCI事件相比,发生并发症的PCI事件调整后的平均成本高6984美元(成本差异的95%置信区间:5801美元,8168美元)。与单纯出血事件、MACCE或出血和MACCE事件相关的增量成本分别为5883美元、5086美元和15,437美元(p<0.0001)。
这项大规模研究突出了与手术并发症相关的巨大经济负担。有必要采取资源和系统方法来尽量减少PCI中的临床和经济并发症。